MedTrace Logo

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream

NCT03462927 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2019-12-24

Study results available
· View outcomes & findings →

Summary

This is a phase 2, randomised, open-label, parallel-group, multicentre trial in which MC2-01 cream and calcipotriene \[CAL\]/betamethasone \[BDP\] ointment (comparator) is investigated in subjects with clinically diagnosed extensive psoriasis vulgaris.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

MC2-01 Cream

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)

DRUG

CAL/BDP combination

Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)

Sponsors & Collaborators

  • MC2 Therapeutics

    lead INDUSTRY

Principal Investigators

  • George Han · Department of Dermatology, Mount Sinai Beth Israel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-08
Primary Completion
2018-08-04
Completion
2018-08-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03462927 on ClinicalTrials.gov